Skip to Content
MilliporeSigma

59352-U

Supelco

Discovery® C8 (5 µm) HPLC Columns

L × I.D. 5 cm × 4.6 mm, HPLC Column

Slide 1 of 1
Sign Into View Organizational & Contract Pricing

Select a Size

1 EA
$635.00

$635.00

Available to ship TODAYDetails

Ships Every 4 weeks

About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Discovery® C8 HPLC Column, 5 μm particle size, L × I.D. 5 cm × 4.6 mm

material

stainless steel column

Quality Level

100

agency

suitable for USP L7

product line

Discovery®

feature

endcapped

manufacturer/tradename

Discovery®

packaging

1 ea of

extent of labeling

7.5% Carbon loading

parameter

≤70 °C temp. range
400 bar pressure (5801 psi)

technique(s)

HPLC: suitable
LC/MS: suitable

L × I.D.

5 cm × 4.6 mm

surface area

200 m2/g

surface coverage

3.4 μmol/m2

impurities

<10 ppm metals

matrix

silica gel, high purity, spherical base material
fully porous particle

matrix active group

C8 (octyl) phase

particle size

5 μm

pore size

180 Å

operating pH range

2-8

application(s)

food and beverages

separation technique

reversed phase

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
59354-U3059354-U569426-U
Discovery&#174; C8 HPLC Column 5&#160;&#956;m particle size, L × I.D. 5&#160;cm × 4.6&#160;mm

Supelco

59352-U

Discovery® C8 HPLC Column

Discovery&#174; C8 HPLC Column 5&#160;&#956;m particle size, L × I.D. 25&#160;cm × 3&#160;mm

Supelco

59354-U30

Discovery® C8 HPLC Column

Discovery&#174; C8 HPLC Column 5&#160;&#956;m particle size, L × I.D. 25&#160;cm × 4.6&#160;mm

Supelco

59354-U

Discovery® C8 HPLC Column

Discovery&#174; C8 HPLC Column 5&#160;&#956;m particle size, L × I.D. 12.5&#160;cm × 4&#160;mm

Supelco

569426-U

Discovery® C8 HPLC Column

particle size

5 μm

particle size

5 μm

particle size

5 μm

particle size

5 μm

matrix active group

C8 (octyl) phase

matrix active group

C8 (octyl) phase

matrix active group

C8 (octyl) phase

matrix active group

C8 (octyl) phase

separation technique

reversed phase

separation technique

reversed phase

separation technique

reversed phase

separation technique

reversed phase

L × I.D.

5 cm × 4.6 mm

L × I.D.

25 cm × 3 mm

L × I.D.

25 cm × 4.6 mm

L × I.D.

12.5 cm × 4 mm

pore size

180 Å

pore size

180 Å

pore size

180 Å

pore size

180 Å

technique(s)

HPLC: suitable, LC/MS: suitable

technique(s)

HPLC: suitable, LC/MS: suitable

technique(s)

HPLC: suitable, LC/MS: suitable

technique(s)

HPLC: suitable, LC/MS: suitable

Features and Benefits

  • Excellent reproducibility
  • Faster separation of strongly hydrophobic analytes than C18 columns
  • Stable, low-bleed LC-MS separations
  • Exceptional peak shapes for basic and acidic compounds
  • Compatible with low organic/highly aqueous mobile phases

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
298758-06
298758-05
298758-04
298758-03
298758-02

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M Q Zhang et al.
Die Pharmazie, 46(10), 687-700 (1991-10-01)
The rapid growth in the quinolone research changed the whole face of the previous SAR concepts. So far structural modifications at all positions of the quinolone nucleus except the 4-oxo group have successfully lead to the discovery of potent antimicrobial
G L Bundy et al.
The Journal of biological chemistry, 261(2), 747-751 (1986-01-15)
The gorgonian coral Pseudoplexaura porosa contains a lipoxygenase capable of converting exogenous arachidonic acid into (8R)-8-hydroperoxy-5,9,11,14-eicosatetraenoic acid. The (8R)- (or 8-L-) configuration in this product, opposite to that observed in previously reported 8-lipoxygenase products, was determined unambiguously by comparison of
Scott C Bell et al.
Pharmacology & therapeutics, 145, 19-34 (2014-06-17)
With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects of cystic fibrosis (CF) commenced. Pharmacological manipulation provides the opportunity to enhance CF transmembrane conductance regulator (CFTR) protein synthesis and/or function. CFTR
Hugo M Botelho et al.
Scientific reports, 5, 9038-9038 (2015-03-13)
Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of
Simeon Grazio et al.
Clinical and experimental rheumatology, 31(5), 665-671 (2013-06-07)
Using proteomic approach in this study, we sought to identify proteins with heparin affinity associated with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and non-inflammatory arthritis (NIA). Plasma samples from adult RA, PsA and NIA patients, 20 of each, were collected.
View All Related Papers

Related Content

Discovery C18 and C8 HPLC Columns

Discovery C18 and C8 HPLC Columns products offered

General Care and Use of Supelco HPLC Columns

General Care and Use of Supelco™ HPLC Columns

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service